Nepafenac
- Generic Name
- Nepafenac
- Brand Names
- Ilevro, Nevanac
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N2O2
- CAS Number
- 78281-72-8
- Unique Ingredient Identifier
- 0J9L7J6V8C
- Background
Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.
- Indication
For the treatment of pain and inflammation associated with cataract surgery.
- Associated Conditions
- Inflammation, Pain
Therapeutic Variables in Cataract Surgery
Phase 4
Completed
- Conditions
- Cataract Surgery
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2007-08-21
- Lead Sponsor
- Innovative Medical
- Registration Number
- NCT00407017
- Locations
- 🇺🇸
The Center for Excellence in Eye Care, Miami, Florida, United States
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo
Phase 3
Completed
- Conditions
- Cataracts
- Interventions
- Other: Nepafenac vehicle eye drops
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 227
- Registration Number
- NCT00405730
- Locations
- 🇫🇷
Bordeaux, Bordeaux, France
Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%
Phase 4
Completed
- Conditions
- Vitrectomy
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- Innovative Medical
- Registration Number
- NCT00377546
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK
Phase 4
Completed
- Conditions
- MyopiaHyperopia
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2006-07-04
- Lead Sponsor
- Center For Excellence In Eye Care
- Target Recruit Count
- 40
- Registration Number
- NCT00347204
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery
Phase 3
Completed
- Conditions
- Cataract
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 267
- Registration Number
- NCT00333255
- Locations
- 🇺🇸
Lehmann Eye Center, Nacogdoches, Texas, United States
Nevanac 3-Month Safety Study With QID Dosing
Phase 3
Completed
- Conditions
- Cataract
- Interventions
- Other: Nepafenac ophthalmic suspension vehicle
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 149
- Registration Number
- NCT00332774
- Locations
- 🇺🇸
Contact Alcon for Trial Locations, Fort Worth, Texas, United States
A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief
Phase 4
Completed
- Conditions
- Photorefractive Keratectomy
- Interventions
- Other: ketorolac 0.4%
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 40
- Registration Number
- NCT00330798
- Locations
- 🇺🇸
Lackland Air Force Base, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath